Galaxy CEO: Strategy has evolved into an overall bitcoin market confidence indicator, with $59,000 as the key support level
BlockBeats news, on June 28, Galaxy Digital CEO Mike Novogratz stated that the core reason for Bitcoin's recent decline is a "collapse in confidence triggered by Strategy." The issue is not just about the Bitcoin price itself, but also the growing concerns in the market regarding Strategy's financing model. As the world's largest publicly traded corporate holder of Bitcoin, Strategy's stocks and preferred securities have become key indicators for traders to assess Bitcoin market risk. Previously, the company’s Bitcoin flywheel effect had come under pressure, and stock trading prices once fell below the value of its Bitcoin holdings. This means that its long-relied strategy of "raising capital through premium-priced share issuance to buy more coins" is now facing challenges. Novogratz pointed out that STRC trading has been sluggish, which should normally stay around $100. Currently, Strategy’s annual dividend obligations have risen to about $1.2 billion, with declining cash reserves cutting the dividend coverage period to roughly 14 months.
Bitcoin is also facing pressure at the macro level. Novogratz summarized the current market logic as "a strong US dollar means weak Bitcoin," with hawkish central bank signals and the strengthening dollar suppressing demand for risk assets. From a technical perspective, the $59,000 to $60,000 range has become a key defense line for Bitcoin; if breached, downside potential may open up to $45,000.
Novogratz also admitted the current situation is complex, with roughly equal probabilities for both a rebound and a deep correction. ETF outflows, weak liquidity, and cautious positioning in the options market further confirm the fragile market sentiment. Now, the health of Strategy’s balance sheet, STRC price performance, and cash positions are not only company-level issues but have evolved into key confidence signals for the overall Bitcoin market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley Analyst Says SpaceX Stock Price Could Double
Getlink reports 550,000,000 shares outstanding, 642,851,718 total voting rights as of Sept. 30, 2026
Getlink disclosed 550,000,000 ordinary shares outstanding as of Sept. 30, 2026. Theoretical voting rights totaled 642,851,718. Exercisable voting rights stood at 635,332,063. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getlink SE published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051200BIZWIRE_USPR_____20261005_BW048564) on October 05, 2026, and is solely responsible for the information contained therein.
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.
Bitcoin Returns Reliant on Major Days -- Market Talk
1105 ET - Bitcoin's strong year-over-year returns are more linked to single days of strong moves, according to Zach Pandl of Grayscale in a note. Pandl says removing bitcoin's five best trading days reduces its three-year return from 225% to 95%, with the return falling to 27% without its 10 best days. If you remove the top fifteen days, it turns a three-year gain into an 11% loss. By comparison, removing the Nasdaq's fifteen best days reduces its cumulative return from 109% to 21%. "Given BTC's return and volatility profile, investors looking for long-term capital appreciation can avoid trying to time the market and instead seek consistent, long-term exposure to the asset," Pandl says. Bitcoin is down 0.2% to $85,610, while ethereum falls 0.2% to $2,701. (kirk.maltais@wsj.com) (END) Dow Jones Newswires October 05, 2026 11:05 ET (15:05 GMT)
Crypto prices
More
